Skip to main content

Table 2 Concentration inhibiting cell viability by 50% (GI50) values for selected tumor cell lines treated with 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), PI-103 or CCT130234

From: Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

Inhibitor (μM) Cell line Two-dimensional Three-dimensional
17-AAG: U-87 MG 0.43 ± 0.13 0.82 ± 0.16
  KNS42 18.02 ± 6.42 81.43 ± 1.60
  MDA-MB-231 P 2.47 ± 0.83 2.33 ± 0.33
  MDA-MB-231 M 0.75 ± 0.10 6.19 ± 0.50
  LICR-LON-HN4 0.07 ± 0.06 0.38 ± 0.11
PI-103: U-87 MG 0.49 ± 0.13 0.16 ± 0.03
  KNS42 2.15 ± 1.20 0.72 ± 0.34
  MDA-MB-231 P 2.39 ± 0.69 > 100
CCT130234: U-87 MG 9.10 ± 1.13 16.40 ± 0.14
  MDA-MB-231 P 11.5 ± 3.32 8.50 ± 0.62
  1. Cells cultured in two dimensions and three dimensions were treated with compounds for 72 h. A CellTiter Glo® viability assay was performed and GI50 values were obtained. Values are means ± SD of the studies reported in Additional file 10 (apart from MDA-MB-231 P that when treated with PI-103 over the concentration range tested, did not achieve a GI50).